Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery

被引:60
作者
Mozar, Fitya Syarifa [1 ]
Chowdhury, Ezharul Hoque [1 ]
机构
[1] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
关键词
PEGylation; protein corona; pharmacokinetics; biodistribution; nanoparticles; tumor regression; tumor accumulation; ACCELERATED BLOOD CLEARANCE; POLYMERIC MICELLE FORMULATION; PHASE-II TRIAL; POLY(ETHYLENE GLYCOL); IN-VIVO; POLYETHYLENE-GLYCOL; GOLD NANOPARTICLES; CREMOPHOR-FREE; GENEXOL-PM; PROTEIN ADSORPTION;
D O I
10.2174/1381612824666180730161721
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PEG-functionalized nanoparticles as carriers of chemotherapeutics agents have been explored with notable successes in preclinical and clinical stages of cancer treatment, with some already approved by FDA, namely PEGylated liposomes and polymers. Half-life extension of therapeutic agents through PEGylation process improves their pharmacokinetic (PK) profiles, thereby reducing their dosing frequency. Protein corona composition of PEGylated nanoparticles (NPs) confers a tremendous influence on their surface characteristics which directly impact tumor accumulation and clearance properties of the drugs. By controlling the size and complexity of PEG molecules, as well as by attaching targeting moieties, the surface characteristics of NPs can be manipulated to improve their tumor uptake without sacrificing the circulation time. This review focuses on design and applications of PEGylated NPs for tumor targeted drug delivery in animal models and clinical setting.
引用
收藏
页码:3283 / 3296
页数:14
相关论文
共 164 条
[61]   The Effect of Nanoparticle Polyethylene Glycol Surface Density on Ligand-Directed Tumor Targeting Studied in Vivo by Dual Modality Imaging [J].
Hak, Sjoerd ;
Helgesen, Emily ;
Hektoen, Helga H. ;
Huuse, Else Marie ;
Jarzyna, Peter A. ;
Mulder, Willem J. M. ;
Haraldseth, Olav ;
Davies, Catharina de Lange .
ACS NANO, 2012, 6 (06) :5648-5658
[62]   Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry [J].
Hama, Susumu ;
Itakura, Shoko ;
Nakai, Mayumi ;
Nakayama, Kayoko ;
Morimoto, Satoshi ;
Suzuki, Satoko ;
Kogure, Kentaro .
JOURNAL OF CONTROLLED RELEASE, 2015, 206 :67-74
[63]   A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation [J].
Hamaguchi, T. ;
Kato, K. ;
Yasui, H. ;
Morizane, C. ;
Ikeda, M. ;
Ueno, H. ;
Muro, K. ;
Yamada, Y. ;
Okusaka, T. ;
Shirao, K. ;
Shimada, Y. ;
Nakahama, H. ;
Matsumura, Y. .
BRITISH JOURNAL OF CANCER, 2007, 97 (02) :170-176
[64]   Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours [J].
Harrington, KJ ;
Rowlinson-Busza, G ;
Uster, PS ;
Stewart, JS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (01) :10-18
[65]   Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles [J].
He, Chunbai ;
Hu, Yiping ;
Yin, Lichen ;
Tang, Cui ;
Yin, Chunhua .
BIOMATERIALS, 2010, 31 (13) :3657-3666
[66]   Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona [J].
Heald, CR ;
Stolnik, S ;
Kujawinski, KS ;
De Matteis, C ;
Garnett, MC ;
Illum, L ;
Davis, SS ;
Purkiss, SC ;
Barlow, RJ ;
Gellert, PR .
LANGMUIR, 2002, 18 (09) :3669-3675
[67]   Novel long-circulating lipid nanocapsules [J].
Hoarau, D ;
Delmas, P ;
David, S ;
Roux, E ;
Leroux, JC .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1783-1789
[68]   Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612
[69]  
Holban AM, 2016, NANOARCHITECTONICS FOR SMART DELIVERY AND DRUG TARGETING, P1
[70]   Pegaspargase: An alternative? [J].
Holle, LM .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) :616-624